Repligen (NASDAQ:RGEN) COO James Bylund Sells 2,191 Shares

Repligen Corporation (NASDAQ:RGEN) COO James Bylund sold 2,191 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer directly owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

James Bylund also recently made the following trade(s):

• On Tuesday, November 18th, James Bylund sold 2,191 shares of Repligen stock. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11.

Repligen Price Performance

NASDAQ:RGEN traded up $2.02 during trading hours on Wednesday, reaching $155.08. 693,747 shares of the company were exchanged, compared to its average volume of 824,500. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.73 billion, a PE ratio of 7,757.88, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The stock’s 50-day moving average is $142.29 and its 200-day moving average is $129.81.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The business had revenue of $188.81 million during the quarter, compared to analysts’ expectations of $181.23 million. During the same quarter in the previous year, the company earned $0.43 earnings per share. The company’s quarterly revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, sell-side analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Institutional Trading of Repligen

Several large investors have recently added to or reduced their stakes in the stock. Danske Bank A S purchased a new position in shares of Repligen during the 3rd quarter worth $107,000. Advisory Services Network LLC acquired a new stake in Repligen during the third quarter worth about $169,000. Armistice Capital LLC purchased a new position in Repligen during the third quarter worth about $316,000. CANADA LIFE ASSURANCE Co boosted its holdings in Repligen by 0.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after purchasing an additional 100 shares during the last quarter. Finally, Woodline Partners LP boosted its holdings in Repligen by 927.0% in the 3rd quarter. Woodline Partners LP now owns 105,449 shares of the biotechnology company’s stock valued at $14,095,000 after purchasing an additional 95,181 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. HSBC started coverage on Repligen in a report on Wednesday, October 1st. They set a “buy” rating and a $150.00 target price for the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Repligen in a research note on Thursday, November 13th. Wells Fargo & Company decreased their price objective on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, July 30th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a report on Tuesday, October 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $173.85.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.